GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing Beilu Pharmaceutical Co Ltd (SZSE:300016) » Definitions » Financial Strength

Beijing Beilu Pharmaceutical Co (SZSE:300016) Financial Strength : 4 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Beijing Beilu Pharmaceutical Co Financial Strength?

Beijing Beilu Pharmaceutical Co has the Financial Strength Rank of 4.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Beijing Beilu Pharmaceutical Co's Interest Coverage for the quarter that ended in Mar. 2024 was 2.28. Beijing Beilu Pharmaceutical Co's debt to revenue ratio for the quarter that ended in Mar. 2024 was 1.01. As of today, Beijing Beilu Pharmaceutical Co's Altman Z-Score is 2.40.


Competitive Comparison of Beijing Beilu Pharmaceutical Co's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Beilu Pharmaceutical Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Beilu Pharmaceutical Co's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beijing Beilu Pharmaceutical Co's Financial Strength distribution charts can be found below:

* The bar in red indicates where Beijing Beilu Pharmaceutical Co's Financial Strength falls into.



Beijing Beilu Pharmaceutical Co Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Beijing Beilu Pharmaceutical Co's Interest Expense for the months ended in Mar. 2024 was ¥-13.8 Mil. Its Operating Income for the months ended in Mar. 2024 was ¥31.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥629.6 Mil.

Beijing Beilu Pharmaceutical Co's Interest Coverage for the quarter that ended in Mar. 2024 is

Interest Coverage=-1*Operating Income (Q: Mar. 2024 )/Interest Expense (Q: Mar. 2024 )
=-1*31.369/-13.761
=2.28

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Beijing Beilu Pharmaceutical Co's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(212.381 + 629.641) / 830.024
=1.01

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Beijing Beilu Pharmaceutical Co has a Z-score of 2.40, indicating it is in Grey Zones. This implies that Beijing Beilu Pharmaceutical Co is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.

Warning Sign:

Altman Z-score of 2.4 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Beilu Pharmaceutical Co  (SZSE:300016) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Beijing Beilu Pharmaceutical Co has the Financial Strength Rank of 4.


Beijing Beilu Pharmaceutical Co Financial Strength Related Terms

Thank you for viewing the detailed overview of Beijing Beilu Pharmaceutical Co's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Beilu Pharmaceutical Co (SZSE:300016) Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Shuiyuan West Road, Miyun District, Beijing, CHN, 100082
Beijing Beilu Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of pharmaceutical products. The products of the company are contrasted agent series, psychotropic, and hypoglycemic products which include iopamidol injection, iodixanol injection, and reglinide tablets.
Executives
Zong Li Directors, executives
Hong Cheng Jie Director
Duan Xian Zhu Directors, executives
Zhu Zhi Director
Wang Dai Xue Director
Li Hong Directors, executives
Liu Ning Directors, executives
Wu Rui Hua Directors, executives
Wu Jie Executives
Liu Dong Long Supervisors
Hong Wei Directors, executives

Beijing Beilu Pharmaceutical Co (SZSE:300016) Headlines

No Headlines